Testing effectiveness (Phase 2)Active Not RecruitingNCT05529316What this trial is testingBotensilimab (AGEN1181) for the Treatment of Advanced MelanomaWho this might be right forAdvanced Melanoma Agenus Inc. 150
Early research (Phase 1)Ended earlyNCT05695898What this trial is testingXmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyWho this might be right forMetastatic MelanomaAdvanced Melanoma University of California, San Francisco 6
Early research (Phase 1)Ended earlyNCT04348916What this trial is testingStudy of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsWho this might be right forCancerMelanomaSolid Tumor+7 more Oncorus, Inc. 66
Testing effectiveness (Phase 2)Looking for participantsNCT06594991What this trial is testingFianlimab, Cemiplimab, and Ipilimumab in People With MelanomaWho this might be right forAdvanced Melanoma Memorial Sloan Kettering Cancer Center 88
Testing effectiveness (Phase 2)Study completedNCT04172454What this trial is testingSafety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsMelanoma Akeso 68
Testing effectiveness (Phase 2)Looking for participantsNCT06425926What this trial is testingSafety and Tolerability Study of GIM-531 in Advanced Solid TumorsWho this might be right forMelanoma Stage IVSolid Tumor Georgiamune Inc 117
Testing effectiveness (Phase 2)WithdrawnNCT06030037What this trial is testingPembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) MelanomaWho this might be right forPD-1 Refractory Advanced Melanoma Diwakar Davar
Testing effectiveness (Phase 2)Ended earlyNCT03595683What this trial is testingPembrolizumab and EDP1503 in Advanced MelanomaWho this might be right forMelanoma (Skin)Melanoma University of Chicago 8
Large-scale testing (Phase 3)Ended earlyNCT03445533What this trial is testingTilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaWho this might be right forMetastatic Melanoma Idera Pharmaceuticals, Inc. 481
Testing effectiveness (Phase 2)Looking for participantsNCT02332668What this trial is testingPembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)Who this might be right forMelanomaLymphomaSolid Tumor+2 more Merck Sharp & Dohme LLC 370
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07040436What this trial is testingAssessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1Who this might be right forAdvanced Melanoma Oncodesign Precision Medicine 41
Testing effectiveness (Phase 2)Study completedNCT04493203What this trial is testingNivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaWho this might be right forAdvanced MelanomaUnresectable Melanoma Yana Najjar 31
Testing effectiveness (Phase 2)Study completedNCT04796194What this trial is testingIntratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced MelanomaWho this might be right forAdvanced Melanoma Lytix Biopharma AS 23
Early research (Phase 1)Looking for participantsNCT05098210What this trial is testingPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more Fred Hutchinson Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT04526899What this trial is testingInvestigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of TreatmentWho this might be right forMelanoma Stage IIIMelanoma Stage IVUnresectable Melanoma BioNTech SE 184
Testing effectiveness (Phase 2)Study completedNCT04577807What this trial is testingLUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory MelanomaWho this might be right forMelanoma Istari Oncology, Inc. 27
Testing effectiveness (Phase 2)WithdrawnNCT05561491What this trial is testingONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWho this might be right forMelanoma Targovax Oy
Testing effectiveness (Phase 2)Study completedNCT03033576What this trial is testingTesting Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Melanoma of Unknown Primary+3 more National Cancer Institute (NCI) 94
Testing effectiveness (Phase 2)Looking for participantsNCT04971499What this trial is testingDapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced MelanomaWho this might be right forMelanoma April Salama, M.D. 26
Early research (Phase 1)Active Not RecruitingNCT02298959What this trial is testingTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerWho this might be right forClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Malignant Solid Neoplasm+12 more National Cancer Institute (NCI) 59